

## PTEN Antibody (N-term)

Purified Mouse Monoclonal Antibody (Mab) Catalog # AM8597b

### Specification

## **PTEN Antibody (N-term) - Product Information**

Application Primary Accession Other Accession Reactivity Predicted Host Clonality Isotype Calculated MW WB,E <u>P60484</u> <u>P60483, 008586, 09PUT6, 054857</u> Human, Mouse, Rat Xenopus Mouse monoclonal IgG1,k 47166

## **PTEN Antibody (N-term) - Additional Information**

### Gene ID 5728

**Other Names** 

Phosphatidylinositol 3, 5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN, 3.1.3.16, 3.1.3.48, 3.1.3.67, Mutated in multiple advanced cancers 1, Phosphatase and tensin homolog, PTEN, MMAC1, TEP1

#### Target/Specificity

This PTEN antibody is generated from a mouse immunized with a KLH conjugated synthetic peptide between 10-44 amino acids from the N-terminal region of human PTEN.

**Dilution** WB~~1:500-1:2000

Format

Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column, followed by dialysis against PBS.

Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

#### Precautions

PTEN Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.

## **PTEN Antibody (N-term) - Protein Information**

Name PTEN



## Synonyms MMAC1, TEP1

Function Dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine-phosphorylated proteins (PubMed:<u>9187108</u>, PubMed:<u>9256433</u>, PubMed:<u>9616126</u>). Also functions as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring of PtdIns(3,4,5)P3/phosphatidylinositol 3,4,5- trisphosphate, PtdIns(3,4)P2/phosphatidylinositol 3,4-diphosphate and PtdIns3P/phosphatidylinositol 3-phosphate with a preference for PtdIns(3,4,5)P3 (PubMed: 16824732, PubMed: 26504226, PubMed: 9593664, PubMed: 9811831). Furthermore, this enzyme can also act as a cytosolic inositol 3-phosphatase acting on Ins(1,3,4,5,6)P5/inositol 1,3,4,5,6 pentakisphosphate and possibly Ins(1,3,4,5)P4/1D-myo-inositol 1,3,4,5- tetrakisphosphate (PubMed:<u>11418101</u>, PubMed:<u>15979280</u>). Antagonizes the PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides and thereby modulating cell cycle progression and cell survival (PubMed: 31492966, PubMed: 37279284). The unphosphorylated form cooperates with MAGI2 to suppress AKT1 activation (PubMed:11707428). In motile cells. suppresses the formation of lateral pseudopods and thereby promotes cell polarization and directed movement (PubMed:22279049). Dephosphorylates tyrosine-phosphorylated focal adhesion kinase and inhibits cell migration and integrin-mediated cell spreading and focal adhesion formation (PubMed: 22279049). Required for growth factor-induced epithelial cell migration; growth factor stimulation induces PTEN phosphorylation which changes its binding preference from the p85 regulatory subunit of the PI3K kinase complex to DLC1 and results in translocation of the PTEN-DLC1 complex to the posterior of migrating cells to promote RHOA activation (PubMed: 26166433). Meanwhile, TNS3 switches binding preference from DLC1 to p85 and the TNS3-p85 complex translocates to the leading edge of migrating cells to activate RAC1 activation (PubMed:<u>26166433</u>). Plays a role as a key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation (By similarity). Involved in the regulation of synaptic function in excitatory hippocampal synapses. Recruited to the postsynaptic membrane upon NMDA receptor activation, is required for the modulation of synaptic activity during plasticity. Enhancement of lipid phosphatase activity is able to drive depression of AMPA receptor-mediated synaptic responses, activity required for NMDA receptor-dependent long-term depression (LTD) (By similarity). May be a negative regulator of insulin signaling and glucose metabolism in adipose tissue. The nuclear monoubiguitinated form possesses greater apoptotic potential, whereas the cytoplasmic nonubiguitinated form induces less tumor suppressive ability (PubMed: 10468583, PubMed: 18716620).

## **Cellular Location**

Cytoplasm. Nucleus. Nucleus, PML body. Cell projection, dendritic spine {ECO:0000250|UniProtKB:O54857}. Postsynaptic density {ECO:0000250|UniProtKB:O54857}. Note=Monoubiquitinated form is nuclear Nonubiquitinated form is cytoplasmic. Colocalized with PML and USP7 in PML nuclear bodies (PubMed:18716620). XIAP/BIRC4 promotes its nuclear localization (PubMed:19473982). Associares with the postsynaptic density in response to NMDAR activation (By similarity) {ECO:0000250|UniProtKB:O54857, ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:19473982}

#### **Tissue Location**

Expressed at a relatively high level in all adult tissues, including heart, brain, placenta, lung, liver, muscle, kidney and pancreas.

## **PTEN Antibody (N-term) - Protocols**


Provided below are standard protocols that you may find useful for product applications.

- <u>Western Blot</u>
- Blocking Peptides
- Dot Blot



- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- <u>Cell Culture</u>

## PTEN Antibody (N-term) - Images



All lanes : Anti-PTEN Antibody (N-term) at 1:500-1:2000 dilution Lane 1: Hela whole cell lysate Lane 2: C6 whole cell lysate Lane 3: NIH/3T3 whole cell lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-mouse IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 47 kDa Blocking/Dilution buffer: 5% NFDM/TBST.

# PTEN Antibody (N-term) - Background

Tumor suppressor. Acts as a dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine- phosphorylated proteins. Also acts as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring from phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3,4-diphosphate, phosphatidylinositol 3- phosphate and inositol 1,3,4,5-tetrakisphosphate with order of substrate preference in vitro PtdIns(3,4,5)P3 > PtdIns(3,4)P2> PtdIns3P > Ins(1,3,4,5)P4. The lipid phosphatase activity is critical for its tumor suppressor function. Antagonizes the PI3K- AKT/PKB signaling pathway by dephosphorylating phosphoinositides and thereby modulating cell cycle progression and cell survival. The unphosphorylated form cooperates with AIP1 to suppress AKT1 activation. Dephosphorylates tyrosine-phosphorylated focal adhesion kinase and inhibits cell migration and integrin-mediated cell spreading and focal adhesion formation. Plays a role as a key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. May be a negative regulator of insulin signaling and glucose metabolism in adipose tissue. The nuclear monoubiguitinated form possesses greater apoptotic potential, whereas the cytoplasmic nonubiguitinated form induces less tumor suppressive ability. In motile cells, suppresses the formation of lateral pseudopods and thereby promotes cell polarization and directed movement.

# PTEN Antibody (N-term) - References

Li D.M., et al.Cancer Res. 57:2124-2129(1997). Steck P.A., et al.Nat. Genet. 15:356-363(1997). Li J., et al.Science 275:1943-1947(1997).



Hamilton J.A., et al.Br. J. Cancer 82:1671-1676(2000). Wang S., et al.Submitted (APR-1997) to the EMBL/GenBank/DDBJ databases.